Yingjiang Zhou Selected Research

PF-05231023

1/2018	Glyco-engineered Long Acting FGF21 Variant with Optimal Pharmaceutical and Pharmacokinetic Properties to Enable Weekly to Twice Monthly Subcutaneous Dosing.
3/2016	A Long-Acting FGF21 Molecule, PF-05231023, Decreases Body Weight and Improves Lipid Profile in Non-human Primates and Type 2 Diabetic Subjects.
1/2016	PF-05231023, a long-acting FGF21 analogue, decreases body weight by reduction of food intake in non-human primates.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Yingjiang Zhou Research Topics

Disease

15	Obesity 03/2016 - 02/2007
10	Insulin Resistance 01/2022 - 02/2007
7	Body Weight (Weight, Body) 01/2018 - 02/2007
5	Type 2 Diabetes Mellitus (MODY) 01/2022 - 11/2010
5	Glucose Intolerance 01/2014 - 02/2007
5	Hyperglycemia 01/2013 - 02/2007
2	Metabolic Diseases (Metabolic Disease) 01/2018 - 12/2011
2	Weight Loss (Weight Reduction) 01/2016 - 12/2011
1	Cardiomegaly (Heart Hypertrophy) 01/2022
1	Overweight 03/2016
1	Inflammation (Inflammations) 06/2013
1	Hyperinsulinism (Hyperinsulinemia) 01/2013
1	Ketosis 06/2012
1	Starvation 06/2012
1	Non-alcoholic Fatty Liver Disease 11/2010
1	Hyperphagia (Overeating) 02/2007
1	Hyperlipidemias (Hyperlipidemia) 02/2007

Drug/Important Bio-Agent (IBA)

12	Glucose (Dextrose)FDA LinkGeneric 01/2022 - 02/2007
5	fibroblast growth factor 21IBA 01/2018 - 07/2015
4	Insulin (Novolin)FDA Link 01/2022 - 03/2011
4	LeptinIBA 06/2013 - 02/2007
3	LipidsIBA 01/2018 - 11/2010
3	PF-05231023IBA 01/2018 - 01/2016
3	Triglycerides (Triacylglycerol)IBA 01/2013 - 12/2011
3	Proteins (Proteins, Gene)FDA Link 01/2013 - 09/2009
2	Fatty Acids (Saturated Fatty Acids)IBA 07/2015 - 11/2011
2	LipocalinsIBA 01/2013 - 11/2011
2	Insulin ReceptorIBA 04/2010 - 09/2009
1	Protein Tyrosine PhosphatasesIBA 01/2022
1	Lipoproteins (Lipoprotein)IBA 03/2016
1	AdiponectinIBA 03/2016
1	Insulin-Like PeptidesIBA 03/2016
1	CholesterolIBA 05/2014
1	Mechanistic Target of Rapamycin Complex 1IBA 01/2014
1	TOR Serine-Threonine KinasesIBA 01/2014
1	Leptin ReceptorsIBA 06/2013
1	Retinol-Binding Proteins (Retinoid Binding Proteins)IBA 01/2013
1	Epinephrine (Adrenaline)FDA LinkGeneric 06/2012
1	Glucagon (Glukagon)FDA Link 06/2012
1	Hormones (Hormone)IBA 06/2012
1	Peptides (Polypeptides)IBA 06/2012
1	Phosphotransferases (Kinase)IBA 06/2012
1	Diacylglycerol O-AcyltransferaseIBA 12/2011
1	Acyl Coenzyme A (Acyl CoA)IBA 12/2011
1	p38 Mitogen-Activated Protein KinasesIBA 09/2011
1	Transcription Factors (Transcription Factor)IBA 03/2011
1	Adenosine Triphosphatases (ATPase)IBA 11/2010
1	Tyrosine (L-Tyrosine)FDA Link 09/2009
1	Insulin Receptor Substrate ProteinsIBA 09/2009
1	Dietary Fats (Dietary Fat)IBA 04/2009
1	Streptozocin (Streptozotocin)FDA Link 04/2009

Therapy/Procedure

2	Therapeutics 01/2022 - 01/2013
1	Drug Therapy (Chemotherapy) 01/2016
1	Oral Administration 12/2011